MedTrace Logo

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

NCT05103046 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-03-12

No results posted yet for this study

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

UCT-03-008

Orally available kinase inhibitor

Sponsors & Collaborators

  • Translational Research in Oncology

    collaborator OTHER

  • 1200 Pharma, LLC

    lead INDUSTRY

Principal Investigators

  • Alex Garcia · TRIO-US

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-23
Primary Completion
2024-12-15
Completion
2025-12-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05103046 on ClinicalTrials.gov